

Depemokimab

Cat. No.:	HY-P99850
CAS No.:	2243274-14-6
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Depemokimab (GSK-3511294) is a long-acting anti-IL-15 monoclonal antibody. Depemokimab can be used for research of asthma ^{[1][2]} .
IC ₅₀ & Target	IL-15 ^[1]
In Vivo	Depemokimab (PK assay in cynomolgus monkeys) shows an approximately 2-fold reduction in clearance compared with Mepolizumab (HY-P9945), and shows an IL-5 binding affinity approximately 30-fold greater than Mepolizumab ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Calzetta L, et al. Investigational Treatments in Phase I and II Clinical Trials: A Systematic Review in Asthma. *Biomedicines*. 2022 Sep 19;10(9):2330.
- [2]. Singh D, et al. A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma. *Br J Clin Pharmacol*. 2022 Feb;88(2):702-712.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA